Latest News about APLS
Recent news which mentions APLS
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Today 14:11 EDT
From Benzinga
From Benzinga
From Benzinga
Earnings Scheduled For February 28, 2025
February 28, 2025
From Benzinga
What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals
February 13, 2025
Tickers
APLS
From Benzinga
Analyst Expectations For Apellis Pharmaceuticals's Future
January 21, 2025
Tickers
APLS
From Benzinga
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
December 17, 2024
From Benzinga
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
December 17, 2024
From Benzinga
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
November 19, 2024
From Benzinga
From Benzinga
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
November 05, 2024
Tickers
APLS
From Motley Fool
Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 05, 2024
From Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 05, 2024
From Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 05, 2024
From Benzinga
A Glimpse of Apellis Pharmaceuticals's Earnings Potential
November 04, 2024
Tickers
APLS
From Benzinga
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
October 29, 2024
From Motley Fool
Navigating 18 Analyst Ratings For Apellis Pharmaceuticals
October 16, 2024
Tickers
APLS
From Benzinga
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
October 16, 2024
From Benzinga
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
September 23, 2024
From Benzinga
What's Going With Apellis Pharmaceuticals Stock Friday?
September 20, 2024
From Benzinga
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
September 13, 2024
Tickers
APLS
From Benzinga
From InvestorPlace
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
August 08, 2024
From Benzinga
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
August 02, 2024
Tickers
APLS
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.